AbSci, a Vancouver-based bioscience company, has announced a collaboration with the global pharmaceutical company Sanofi, which is headquartered in France.
The partnership will see AbSci’s SoluPro platform used to aid in the manufacture of two of Sanofi’s biotheraputic molecules. An AbSci spokesperson said the company is unable to disclose what the molecules are or what they’re used for. The work will take place at AbSci and will be funded by Sanofi.
SoluPro uses modified E. coli bacteria to quickly create specific proteins and peptides such as insulin. AbSci touts the product as a tool to help manufacturers speed up research and scale up production of therapeutic molecules and proteins that are traditionally difficult to produce.
Sean McClain founded AbSci in 2011 and initially operated out of Portland State University’s Business Accelerator. The company moved into its Hudson Building headquarters in Vancouver in 2016.
